文献速递脑血管病外科神经重症

脑动静脉畸形的多模式治疗:12年经验及关键结局与ARUBA试验的比较

Multimodal cerebral arteriovenous malformation treatment: a 12-year experience and comparison of key outcomes to ARUBA.
PubMed 文献 · J Neurosurg · 2019-11-01

作者回顾性分析本机构连续收治的318例成人脑动静脉畸形(AVM)患者,均接受栓塞、手术和(或)质子束放射外科治疗;在142例符合ARUBA入组条件的患者中分析结局,并与ARUBA试验及自然病史队列比较。结果显示该多模式治疗的关键安全性终点优于ARUBA干预组、与ARUBA内科治疗组相似,长期随访结果优于自然病史队列。

要点

  • 本队列年化卒中率为1.8%,首12个月为4.9%,12个月后为0.8%。
  • 症状性卒中(ARUBA主要终点)发生13例(9.2%),与ARUBA内科治疗组(9.2%,p=1.0)相似。
  • 随访5年mRS评分≥2(ARUBA次要终点)者为14.3%,低于ARUBA干预组的40.5%(p=0.002)。

核心结论

  • 对脑AVM患者采用多模式选择与治疗可获得良好临床结局:卒中、死亡和mRS评分0-1等关键安全性终点优于ARUBA干预组,与ARUBA内科治疗组在5年随访时相似;较长随访时结果优于自然病史队列。
  • 作者认为,具备整合诊疗方案、患者选择经验和个体化治疗策略的三级医疗中心可能获得优于ARUBA所报告结果的临床结局;这支持现有登记研究,并值得考虑未来在脑AVM患者中开展随机对照试验。

研究设计与样本

  • 回顾性分析本机构连续收治的318例接受栓塞、手术和(或)质子束放射外科治疗的成人脑AVM患者。
  • 在142例符合ARUBA入组条件(基线改良Rankin量表[mRS]评分0-1、无出血史)的患者中进行分析,并与ARUBA主要和次要结局及自然病史队列比较。

主要发现

  • 本队列年化卒中率(出血性或缺血性)为1.8%,首12个月为4.9%,12个月后为0.8%,低于自然病史研究和ARUBA内科治疗组(p=0.001)。
  • ARUBA主要终点症状性卒中达13例(9.2%),与ARUBA干预组(39.6%,p=0.0001)相比更优,与ARUBA内科治疗组(9.2%,p=1.0)相似。
  • ARUBA次要终点(随访5年时mRS评分≥2)达14.3%,而ARUBA干预组为40.5%(p=0.002),ARUBA内科治疗组为16.7%(p=0.6)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Curative treatment of unruptured brain arteriovenous malformations (AVMs) remains controversial after the only randomized controlled trial, A Randomized Trial of Unruptured Brain Arteriovenous Malformations (ARUBA), was halted prematurely because interim analysis revealed superiority of the medical management group. In contrast, meta-analyses of retrospective cohorts suggest that intervention is much safer than was found in ARUBA. METHODS: The authors retrospectively analyzed 318 consecutive adult patients with brain AVMs treated at their institution with embolization, surgery, and/or proton beam radiosurgery. Analysis was performed in 142 ARUBA-eligible patients (baseline modified Rankin Scale [mRS] score 0-1, no history of hemorrhage), and results were compared to primary and secondary outcomes from ARUBA, as well as to natural history cohorts. RESULTS: The annualized stroke rate (hemorrhagic or ischemic) in this cohort was 1.8%, 4.9% in the first 12 months and 0.8% after the first 12 months, which was lower than in natural history studies and the ARUBA medical management arm (p = 0.001). The primary ARUBA endpoint of symptomatic stroke was reached in 13 patients (9.2%), which compares favorably to the ARUBA intervention arm (39.6%, p = 0.0001) and is similar to the ARUBA medical management arm (9.2%, p = 1.0). The secondary ARUBA endpoint (mRS score ≥ 2 at 5 years of follow-up) was reached in 14.3% of patients, compared to 40.5% in the ARUBA intervention arm (p = 0.002) and 16.7% in the ARUBA medical management arm (p = 0.6). CONCLUSIONS: This multimodal approach to the selection and treatment of patients with brain AVMs yields good clinical outcomes with key safety endpoints (stroke, death, and mRS score 0-1) better than the ARUBA intervention arm and similar to the ARUBA medical arm at 5 years of follow-up. Results compare favorably to natural history cohorts at longer follow-up times. This suggests that tertiary care centers with integrated programs, expertise in patient selection, and individualized treatment approaches may allow for better clinical outcomes than reported in ARUBA. It supports current registry studies and merits consideration of future randomized controlled trials in patients with brain AVMs.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Pulli B, Chapman PH, Ogilvy CS, et al. Multimodal cerebral arteriovenous malformation treatment: a 12-year experience and comparison of key outcomes to ARUBA. J Neurosurg. 2019. PMID: 31675689. doi:10.3171/2019.8.JNS19998

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。